自体CAR-T类治疗产品产能研究关注点浅析  被引量:2

A brief analysis of the focus of production capacity research of autologous CAR-T therapeutic products

在线阅读下载全文

作  者:王雪 马岩松 韦薇 何伍 WANG Xue;MA Yan-song;WEI Wei;HE Wu(Center for Drug Evaluation,National Medical Products Administration,Beijing 100076,China;Center for Food and Drug Inspection,National Medical Products Administration,Beijing 100076,China)

机构地区:[1]国家药品监督管理局药品审评中心,北京100076 [2]国家药品监督管理局食品药品审核查验中心,北京100076

出  处:《中国新药杂志》2023年第24期2447-2451,共5页Chinese Journal of New Drugs

摘  要:自体嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)治疗产品在肿瘤治疗尤其是血液系统肿瘤治疗方面为患者带来了显著的生存获益,但自体CAR-T类治疗产品常见的生产模式流程复杂、周期较长,造成该类产品的产能在一定程度上限制了其临床应用。本文结合当前研究进展,在针对自体CAR-T细胞产品常见生产模式分析的基础上,提出自体CAR-T类治疗产品产能确认研究和产能变更研究内容与评价考虑,以期能促进此类产品的研发和临床应用。Autologous chimeric antigen receptor T cell(CAR-T)cell therapy products have brought significant survival benefits to tumor patients,especially in the treatment of hematologic tumors.However,the common production mode of autologous CAR-T therapy products is complicated and has a long cycle.As a result,the production capacity of this kind of products has limited their clinical application to a certain extent.In this paper,based on the analysis of the common production mode of autologous CAR-T cell products,the content and evaluation of the capacity confirmation study and capacity change study of autologous CAR-T therapeutic products are proposed in combination with the current research progress,hoping to effectively promote the development and clinical application of such products.

关 键 词:自体CAR-T 产能研究 审评考虑 

分 类 号:R95[医药卫生—药学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象